Adams Respiratory Therapeutics, Inc. (1319439) SEC Filing 10-Q Quarterly report for the period ending Sunday, December 31, 2006

Adams Respiratory Therapeutics, Inc.

CIK: 1319439

Exhibit 99.1
Strong top-line performance driven by higher sales of
Mucinex® DM, Delsym®, and Children’s Mucinex®
Second Quarter Financial Highlights:
    Net sales increased 75% to $110.6 million.
    Selling, marketing and administrative expenses increased $26 million to $56 million, including investments in selling and consumer marketing programs.
    Diluted earnings per share increased 17% to $0.34, inclusive of a non-cash, pre-tax charge of $2.7 million, or $0.04 per diluted share, related to the AlleRx royalty interest.
Second Quarter Operational Highlights:
    Gained a leading position in the over-the-counter (OTC) cough, cold, allergy, sinus (C/C/A/S) category with a total share of 11.9 percent of the market, according to Information Resources Inc. (IRI) data for the 4-week period ending Dec. 31, 2006, an increase of 5.2 market share points versus the prior-year period.
    Completed the clinical portion of the Phase IIb trial of erdosteine in December. The Company awaits top-line results.
    Submitted a New Drug Application (NDA) to the FDA for the first extended-release guaifenesin combination prescription product for cough. (Dec.)
CHESTER, N.J. (Feb. 7, 2007) – Adams Respiratory Therapeutics, Inc. (NASDAQ: ARxT) today announced financial results for the fiscal second quarter ended Dec. 31, 2006.
Commenting on the Company’s fiscal 2007 second quarter results, Michael J. Valentino, president and CEO said, “I am really excited by our performance this quarter. We produced solid results and we continued to make significant and strategically important investments to further develop our business. We achieved strong top-line growth across our product line which produced healthy increases in both net income and diluted earnings per share in the fiscal 2007 second quarter.”


The following information was filed by Adams Respiratory Therapeutics, Inc. on Wednesday, February 7, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Adams Respiratory Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adams Respiratory Therapeutics, Inc..


Assess how Adams Respiratory Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adams Respiratory Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2007 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1319439
Form Type: 10-Q Quarterly Report
Accession Number: 0000950144-07-001231
Submitted to the SEC: Wed Feb 14 2007 2:46:43 PM EST
Accepted by the SEC: Wed Feb 14 2007
Period: Sunday, December 31, 2006
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink: